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Abstract
Purpose To verify sufficient progesterone supplementa-
tion during the luteal phase and to determine the efficacy
and safety of a natural micronized progesterone vaginal
tablet (FE 999913) in Japanese women undergoing in vitro
fertilization-embryo transfer or intracytoplasmic sperm
injection.
Methods In a multi-center, randomized, open-label, par-
allel group trial, 108 subjects were randomized to receive
FE 999913 vaginally twice daily (n = 54) or three times
daily (n = 54) for up to 10 weeks. Primary endpoints were
the proportion of subjects with serum progesterone con-
centration C10 ng/ml on day 5 and ongoing pregnancy rate
at week 5.
Results Ninety-four subjects completed the trial and 90
subjects underwent embryo transfer. The proportion of
subjects with serum progesterone concentration C10 ng/ml
on day 5 was 98.9 % and the lower limit of 95 % CI of the
difference between the current trial and MEGASET trial
was -3.6 %, which was within the non-inferiority crite-
rion. The ongoing pregnancy rate was 22.2 %, which is
similar to that in actual clinical settings in Japan. No safety
concerns were observed.
Conclusions FE 999913 was useful in this trial from the
aspects of sufficient supplementation of progesterone,
comparable pregnancy rate with that in clinical practice in
Japan, and safety.
Clinical trial registration ClinicalTrials.gov identifier:
NCT01710514.
Keywords Assisted reproductive technology (ART)  FE
999913  Luteal support  Pregnancy rate  Vaginal insert
Introduction
Luteal support in assisted reproductive technology (ART)
is important to maintain implantation after embryo transfer
and to improve pregnancy rates. Luteal phase deficiency
(luteal dysfunction) may result from controlled ovarian
stimulation (COS) by hormonal management using gona-
dotropin-releasing hormone (GnRH) agonists or GnRH
antagonists in ART [1–3]. Therefore, hormone replacement
with exogenous progesterone or activation of the corpus
luteum by administration of human chorionic gonadotropin
(hCG) is necessary for implantation after embryo transfer
and maintenance of pregnancy. Luteal activation or luteal
support with hCG improves pregnancy rates [4, 5], but may
result in the onset of ovarian hyperstimulation syndrome
(OHSS) [6–9] and should therefore not be used by patients
with a high risk of OHSS. Exogenous progesterone, on the
other hand, does not cause OHSS [10]. Administration of
exogenous progesterone is considered to be a useful
method of luteal support therapy in ART treatment in Japan
and worldwide.
Approved progesterone preparations in Japan are limited
to injectable solutions and oral synthetic preparations
indicated for the treatment of amenorrhea, dysmenorrhea,
menometrorrhagia, infertility due to luteal phase defect,
threatened abortion/premature labor, and habitual abortion.
There are no approved vaginal progesterone preparations,
nor approved progesterone preparations with the indication
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of luteal support in ART. Therefore, progesterone is used
off-label in Japan, mainly as progesterone intramuscular
(IM) injections or oral synthetic progesterone preparations.
Treatment with IM progesterone injections involves daily
administration, which imposes a temporal and physical
burden on patients. Daily injections are associated with a
risk of injection site pain, nerve injury, and muscle con-
tracture. The extent of the use of oral synthetic proges-
terone preparations in luteal support is unknown and for
some of these preparations there are concerns regarding
possible effects on the fetus [1]. Oral synthetic proges-
terone preparations are rarely used worldwide [11].
Foreign progesterone vaginal preparations are being
unofficially imported or dispensed by the in-house phar-
macies at some medical institutions [12]. However, there
are concerns regarding not only the quality of these
preparations but also the development of adverse drug
reactions and compensation and relief if such reactions
develop. In the European Union and the US, vaginal pro-
gesterone preparations are used as a standard therapy for
luteal support in infertility treatment [11, 12]. In Japan,
however, there is an unmet medical need for progesterone
supplementation during ART. Therefore, the Japan Society
of Fertilization and Implantation and the non-profit orga-
nization Fertility Information Network (Fine) filed a
request for ‘‘addition of a vaginal dosage form for luteal
supplementation during in vitro fertilization and embryo
transfer (IVF-ET)’’ to the Ministry of Health, Labor, and
Welfare, which subsequently recruited a corporation to
develop the requested vaginal preparation.
FE 999913 is a natural micronized progesterone effer-
vescent vaginal tablet that contains 100 mg of progesterone
per tablet as its active ingredient. It can be reliably
administered by insertion vaginally using a dedicated
applicator. As of October 2014, the FE 999913 vaginal
tablet has been approved in 37 countries and territories
worldwide including Japan, the US, and the UK, and is
indicated for luteal support as part of an ART treatment
program for infertile women.
The present investigation is a phase III clinical trial
conducted to confirm the efficacy and safety of FE 999913
in an actual clinical setting in Japan.
Materials and methods
This trial was a multi-center, randomized, open-label,
parallel group phase III trial performed in 108 Japanese
women of reproductive age undergoing IVF-ET or intra-
cytoplasmic sperm injection (ICSI).
The trial was designed to verify sufficient supplemen-
tation of progesterone during vaginal administration of
100 mg FE 999913 (LUTINUS; Ferring Pharmaceuticals)
twice daily (BID) or three times daily (TID) and to deter-
mine the efficacy and safety of FE 999913.
The trial was conducted at six sites in Japan from
October 2012 to August 2013 and was conducted in
accordance with the Declaration of Helsinki and its
amendments in force at the initiation of the trial, in
compliance with the approved protocol, international
conference on harmonization—good clinical practice,
Japanese good clinical practice and applicable regula-
tory requirements. The trial was approved by an insti-
tutional review board at each site before the initiation
of the trial.
Trial population
Enrolled trial subjects were Japanese women of reproduc-
tive age who met the following inclusion criteria; (1) early
follicular phase (day 2–4) follicle stimulating hormone
concentration B12 IU/l and estradiol concentration\100
pg/ml; (2) luteinizing hormone, prolactin, and thyroid-
stimulating hormone within the normal limits for the
clinical laboratory, or considered not clinically significant
by the investigator within 6 months prior to screening; (3)
a documented history of infertility [e.g., unable to conceive
for at least 1 year (or for 6 months for women C38 years
of age) or bilateral tubal occlusion or absence]; (4)
transvaginal ultrasound (TVU) at screening (or within
14 days prior to screening) consistent with findings ade-
quate for ART with respect to uterus and adnexa (periph-
eral reproductive organs); (5) at least one cycle with no
fertility medication prior to screening; (6) hysterosalpin-
gography, hysteroscopy, sonohysterogram, or TVU docu-
menting a normal uterine cavity; (7) consent to
contraception during the cycle in which pituitary down
regulation was performed (prior to start of COS); and (8)
signed informed consent to fertility treatment using
FE 999913 after the subject and her husband had thor-
oughly understood the content.
Main exclusion criteria were the following: donor
oocyte or embryo recipients; women with a body mass
index (BMI) of[34 kg/m2; women with a poor response to
gonadotropins; women with current or recent (within the
past 12 months) substance abuse; women currently breast
feeding, pregnant, or with a contraindication to pregnancy;
women who refused to or were unable to comply with the
trial procedures/conditions in the protocol; women who
had participated in any experimental drug trial within
60 days prior to screening; women with a history of C3
spontaneous miscarriages and women with severe hepatic
dysfunction or hepatic disease.
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Treatment regimen
COS was performed using the long GnRH agonist protocol
or GnRH antagonist protocol according to the procedures
of the trial site. Subjects meeting all eligibility criteria at
screening were randomized to either the BID group or the
TID group on the day of oocyte retrieval and administra-
tion of FE 999913 was initiated on the day following
oocyte retrieval. Embryo transfer was performed on day 3
or day 5 after oocyte retrieval in accordance with the
standard procedures of the trial site. Treatment with
FE 999913 continued for up to 10 weeks if pregnancy was
confirmed. A serum b-hCG pregnancy test was performed
at week 2 of treatment, and subjects were assessed for
clinical pregnancy at week 4 of treatment and for ongoing
pregnancy at week 5 of treatment.
Trial endpoints
The primary endpoints were: (1) the proportion of subjects
with serum progesterone concentrationC10 ng/ml on day 5
of treatment and (2) the ongoing pregnancy rate (confir-
mation of fetal heart movements on TVU at week 5 of
treatment). Only a subset of the randomized subjects had
embryos available for transfer. The availability of embryos
for transfer was not related to FE 999913. Therefore the
evaluation of the ongoing pregnancy rate was based on the
subjects who underwent embryo transfer. Secondary end-
points included the positive b-hCG rate at week 2 of
treatment, the clinical pregnancy rate (defined as presence
of a gestational sac on TVU at week 4 of treatment) and the
serum progesterone concentration throughout the treatment.
The safety of FE 999913 was evaluated by frequency
and severity of adverse events, clinical laboratory tests
(biochemistry, hematology, and urinalysis), 12-lead elec-
trocardiogram, physical examinations and gynecological
examinations.
Sample size and statistical analysis
This trial was powered with respect to the first co-primary
endpoint, the proportion of subjects with serumprogesterone
concentration C10 ng/ml on day 5 of treatment. The target
was to demonstrate non-inferiority against a historical con-
trol (the overseas MEGASET trial [13]), in which 631/632
(99.8 %) women had a progesterone concentration C10 ng/
ml on day 5 of progesterone administration. The non-infe-
riority limit was set to -10.0 % (absolute). Assuming that
the probability of having a progesterone concentration
C10 ng/ml is 98.5 % and using a non-inferiority margin of
-10.0 % (absolute), a total sample size of 80 subjects yiel-
ded more than 80 % power for establishing non-inferiority
using a two-sided 95 % confidence interval (CI, corre-
sponding to using a one-sided alpha of 2.5 %).
The efficacy was analyzed using the full analysis set
(FAS). For quantitative variables, the number of subjects,
mean ± standard deviation (SD), and maximum and min-
imum are shown. For qualitative variables, the number of
subjects and proportion of subjects in each category are
shown. The first co-primary endpoint was verified by
comparing the proportion of subjects with serum proges-
terone concentration C10 ng/ml on day 5 of treatment
observed in this trial to the proportion observed in the
MEGASET trial [13] using a non-inferiority argument
based on the two-sided 95 % CI. For the second co-primary
endpoint, the ongoing pregnancy rates at week 5 of treat-
ment in the subjects with embryo transfer were calculated
for each treatment group, along with two-sided 95 % CIs.
The positive b-hCG rate and clinical pregnancy rate were
analyzed in the same manner as the ongoing pregnancy
rate. The intention-to-treat (ITT) population was included




A total of 145 subjects were screened to participate in the
trial, 37 subjects of whom were screening failures. The
most common reason for screening failure was that inclu-
sion/exclusion criteria were not met. Thus, 108 eligible
subjects were randomized to receive FE 999913.
A total of 94 subjects (87.0 %) completed the trial and
14 subjects (13.0 %) discontinued the trial. The most
common reason for discontinuation was an adverse event,
with six subjects (11.1 %) in the BID group and seven
subjects (13.0 %) in the TID group. One subject in the BID
group discontinued due to withdrawn consent.
The ITT population included all 108 randomized sub-
jects (54 in the BID group and 54 in the TID group). The
FAS, defined as all randomized and exposed subjects with
at least one completed primary efficacy assessment after
treatment initiation, included 94 subjects (46 in the BID
group and 48 in the TID group). The FAS with embryo
transfer population included 90 subjects (43 in the BID
group and 47 in the TID group).
Baseline characteristics
In the FAS with embryo transfer population, subjects were
Japanese women with a mean age of 34.7 years (range,
26–42 years), and the mean BMI was 21.3 kg/m2 (range,
16.0–28.0 kg/m2). The mean duration of infertility was
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42.8 months (range, 9–137 months), and the most common
cause of infertility was male factor (32 subjects, 35.6 %).
The mean number of embryos transferred was 1.1. A total
of 81 subjects (90.0 %) received one embryo and 83 sub-
jects (92.2 %) underwent embryo transfer on day 3 after
oocyte retrieval. Forty subjects underwent IVF-ET and 50
subjects underwent ICSI. No differences were seen
between treatment groups in terms of baseline character-
istics (Table 1).
In the FAS, the mean duration of treatment
(mean ± SD) was 27 ± 21 days, with a range of
3–72 days.
Serum progesterone concentration
The proportion of subjects in the FAS with a serum proges-
terone concentration C10 ng/ml on day 5 of treatment was
98.9 % (95 %CI 94.2; 100.0, 93/94 subjects) (Table 2). In the
MEGASET trial [13] this proportion was 99.8 % (95 % CI
99.1; 100.0, 631/632 subjects). The lower limit of the 95 %CI
of the difference between the proportion of subjects with
serum progesterone concentration C10 ng/ml on day 5 of
treatment in the current trial and the MEGASET trial was
-3.6 %, which exceeded the non-inferiority criterion




Demographic data FE 999913 BID FE 999913 TID Total
FAS with embryo transfer (N) 43 47 90
Age (years)
Mean ± SD 35 ± 3.5 34.5 ± 4.3 34.7 ± 3.9
Range 26–42 26–41 26–42
Age group N (%)
\35 years 16 (37.2 %) 21 (44.7 %) 37 (41.1 %)
35–37 years 16 (37.2 %) 14 (29.8 %) 30 (33.3 %)
38–40 years 10 (23.3 %) 7 (14.9 %) 17 (18.9 %)
41–42 years 1 (2.3 %) 5 (10.6 %) 6 (6.7 %)
BMI (kg/m2)
Mean ± SD 21.2 ± 2.8 21.3 ± 2.9 21.3 ± 2.9
Range 16–27.9 17.2–28 16–28
Duration of infertility (months)
Mean ± SD 42.1 ± 27.4 43.3 ± 23.1 42.8 ± 25.1
Range 9–137 13–101 9–137
Primary cause for infertility N (%)
Unexplained 11 (25.6 %) 12 (25.5 %) 23 (25.6 %)
Tubal factor 16 (37.2 %) 14 (29.8 %) 30 (33.3 %)
Male factor (mild) 2 (4.7 %) 6 (12.8 %) 8 (8.9 %)
Male factor (moderate) 8 (18.6 %) 5 (10.6 %) 13 (14.4 %)
Male factor (severe) 2 (4.7 %) 9 (19.1 %) 11 (12.2 %)
WHO Group I anovulatory infertility 2 (4.7 %) 2 (2.2 %)
WHO Group II anovulatory infertility 1 (2.3 %) 1 (1.1 %)
Other 1 (2.3 %) 1 (2.1 %) 2 (2.2 %)
Day of transfer N (%)
Day 3 embryo transfer 38 (88.4 %) 45 (95.7 %) 83 (92.2 %)
Day 5 embryo transfer 5 (11.6 %) 2 (4.3 %) 7 (7.8 %)
Subjects with embryo transferred N (%)
1 embryo 39 (90.7 %) 42 (89.4 %) 81 (90.0 %)
2 embryos 4 (9.3 %) 5 (10.6 %) 9 (10.0 %)
Embryos transferred (mean ± SD) 1.09 ± 0.294 1.11 ± 0.312 1.1 ± 0.302
Method of insemination N (%)
IVF 19 (44.2 %) 21 (44.7 %) 40 (44.4 %)
ICSI 24 (55.8 %) 26 (55.3 %) 50 (55.6 %)
FAS full analysis set, BID bis in die/twice daily, TID ter in die/three times daily, SD standard deviation,
BMI body mass index, WHO World Health Organization, IVF in vitro fertilization, ICSI intracytoplasmic
sperm injection
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The mean serum progesterone concentrations in the 20
subjects in whom ongoing pregnancy was confirmed at
week 5 of treatment were 78.2 (day 5), 55.9 (week 2), 64.2
(week 4), 57.1 (week 5), 49.8 (week 8), and 48.4 ng/ml
(end of trial). The mean serum progesterone concentrations
sustained at the Japanese standard level during mid-luteal
phase (C10 ng/ml) throughout the 10 weeks, and no
marked changes were seen (Fig. 1).
Pregnancy rates
In the FAS with embryo transfer population, the second co-
primary endpoint, the ongoing pregnancy rate at week 5 of
treatment was 22.2 % (95 % CI 14.1; 32.2, 20/90 subjects)
(Table 3). The clinical pregnancy rate was the same as the
ongoing pregnancy rate; however, one pregnancy loss
occurred in the BID group between week 2 and week 4.
Stratified analysis of the ongoing pregnancy rate in the
FAS with embryo transfer was conducted using subgroups
based on the day of embryo transfer, the number of
embryos transferred, the primary cause for infertility, BMI,
age, protocol type, and method of insemination.
There was no difference (p = 1.000, Fisher’s exact test)
in the ongoing pregnancy rate between the BID and TID
groups in subjects younger than 35 years of age; 18.8 % (3/
16 subjects) in the BID group and 14.3 % (3/21 subjects) in
the TID group, while the ongoing pregnancy rate in the
TID group was significantly higher in subjects 35 years or
more; 11.1 % (3/27 subjects) in the BID group and 42.3 %
(11/26 subjects) in the TID group (p = 0.014, Fisher’s
exact test) (Table 4).
No distinct trends were observed in the ongoing preg-
nancy rates of the other subgroups.
Safety
The overall incidence of adverse events was 35.2 % (38
subjects, 51 events) in the 108 subjects in the safety
Table 2 Proportion of subjects with serum progesterone concentration C10 ng/ml on day 5 of treatment-FAS
FE 999913 (BID/TID)a MEGASET trial progesterone preparationb Differencec
Nd Ne Estimate (%) 95 % CIf Nd Ne Estimate (%) 95 % CIf Estimate (%) 95 % CIg
94 93 98.9 94.2; 100.0 632 631 99.8 99.1; 100.0 -0.9 -3.6;1.8
FAS full analysis set, BID bis in die/twice daily, TID ter in die/three times daily
a Data from the BID group and TID group were pooled
b Historical control
c Difference = the current trial - the MEGASET trial
d Total number of subjects
e Number of subjects with serum progesterone concentration C10 ng/ml on day 5 of treatment
f 95 % CI was calculated based on the exact Clopper–Pearson method









Baseline Day 5 Week 2 Week 4 Week 5 Week 8 End of Trial
100mg BID (n) 6 6 6 6 6 5 6
100mg TID (n) 14 14 14 14 14 12 14























Fig. 1 Serum progesterone
concentration profile
(mean ± SD) in subjects who
were confirmed to be ongoing
pregnant at week 5. This figure
shows the mean serum
progesterone concentration
between day 5 and the end of
trial in the 20 subjects in whom
ongoing pregnancy was
confirmed at week 5. In both
treatment groups (100 mg BID:
bis in die/twice daily, 100 mg
TID: ter in die/three times
daily), mean serum
progesterone concentration
sustained over 10 ng/ml
throughout the treatment and no
marked change was seen
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population. The incidence of serious adverse events (SAE)
was 0.9 % (one subject, one event), and the incidence of
adverse events that led to discontinuation was 8.3 % (nine
subjects, nine events). The incidence of adverse events for
which a causal relationship to FE 999913 could not be
ruled out was 8.3 % (nine subjects, 12 events).
The most common adverse event in the safety popula-
tion was OHSS at an incidence of 20.4 % (22 subjects). No
cases of OHSS were judged to be severe in intensity, and
the majority of cases were mild. A relationship to
FE 999913 was ruled out for all cases of OHSS that
occurred. Other common adverse events were abdominal
distension (3.7 %, four subjects) and vaginal bleeding
(3.7 %, four subjects).
One adverse event led to hospitalization (subchorionic
hemorrhage), but was judged as not related to FE 999913
by the investigator.
The most common adverse events for which relationship
to FE 999913 could not be ruled out were headache,
somnolence, vaginal bleeding (1.9 %, two subjects each).
The profile of adverse events that were seen relatively
frequently was similar between the BID group and the TID
group.
Also, there were no clinically significant trends either
within or between treatment groups with respect to clinical
laboratory tests, vital signs, ECG, physical examination,
and gynecological examination.
Discussion
The current trial was the first randomized trial evaluating
the efficacy and safety of vaginal administration of pro-
gesterone in Japanese women undergoing IVF-ET or ICSI.
Serum progesterone level with FE 999913
This trial demonstrated that the administration of
FE 999913 100 mg BID or TID could maintain serum
progesterone concentrations at C10 ng/ml, which is the
lower reference level of the mid-luteal phase criterion in
Japanese women. FE 999913 also maintained a high serum
progesterone concentration (mean values *50 ng/ml)
throughout the treatment period in subjects who became
pregnant.
The proportion of subjects with a serum progesterone
concentration of C10 ng/ml on day 5 of treatment was
compared with the results from an overseas clinical trial
(MEGASET trial [13]). The proportion of subjects with
serum progesterone concentration C10 mg/ml on day 5 of
treatment in the current trial fulfilled the non-inferiority
criterion relative to the results of the MEGASET trial.
Furthermore, the daily dosage of progesterone used in the
current trial was 200 or 300 mg. Nonetheless, non-inferi-
ority to the vaginal high-dose (600 mg) progesterone cap-
sule that was used in the MEGASET trial
(UTROGESTAN: not approved in Japan) was verified.
Pregnancy rate of FE 999913
The ongoing pregnancy rate per embryo transfer at week 5
of treatment in this trial was 22.2 % (20/90 subjects; BID
group: 14.0 %, TID group: 29.8 %). This pregnancy rate is
comparable to the pregnancy rates in Japanese clinical
trials of the already approved ART drugs FOLLISTIM
injection and GANIREST subcutaneous injection (22.9 %;
35/153 subjects and 25.6 %; 20/78 subjects, respectively)
[14, 15].
The clinical pregnancy rate at week 4 of treatment
(22.2 %, 20/90 subjects) was comparable to the pregnancy
rates listed in the ‘‘Report of the Registration and Survey
Subcommittee of the 2012 Ethics Committee’’ of the Japan
Society of Obstetrics and Gynecology (20.8 %; IVF-ET:
Table 3 Ongoing pregnancy rates—FAS with embryo transfer
Treatment group Na Nb Estimate (%) 95 % CIc
Ongoing pregnancy rate
BID 43 6 14.0 5.3; 27.9
TID 47 14 29.8 17.3; 44.9
Total 90 20 22.2 14.1; 32.2
FAS full analysis set, BID bis in die/twice daily, TID ter in die/three
times daily
a Total number of subjects
b Number of subjects with confirmed ongoing pregnancy
c 95 % CI was calculated based on the exact Clopper–Pearson
method
Table 4 Ongoing pregnancy rates by age—FAS with embryo
transfer
Treatment group Na Nb Estimate (%) p valuec
Ongoing pregnancy rate
\35 years
BID 16 3 18.8 1.000
TID 21 3 14.3
C35 years
BID 27 3 11.1 0.014
TID 26 11 42.3
FAS full analysis set, BID bis in die/twice daily, TID ter in die/three
times daily
a Total number of subjects
b Number of subjects with confirmed ongoing pregnancy
c P value was calculated based on Fisher’s exact test
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22.6 %, ICSI—ejaculation sperm: 19.0 %, ICSI—testicu-
lar sperm extraction sperm: 15.3 %) [16].
Although the objective of this trial was not to compare
and determine the efficacy of the two dose regimens, a
numeric difference in the ongoing pregnancy rates was
observed between the BID group (14.0 %, 6/43 subjects)
and the TID group (29.8 %, 14/47 subjects). There were no
differences in demographic variables between the two
treatment groups. The ongoing pregnancy rate varied from
10 to 57 % depending on the site, and some sites had
pregnant subjects only in the BID group or the TID group.
Thus, it appears that there was no essential difference in the
pregnancy rate between the BID and the TID groups, and
the numeric difference between two groups was incidental.
In addition, the ongoing pregnancy rate in subjects
35 years or more (42.3 %, 11/26 subjects) was higher than
that in subjects younger than 35 years (14.3 %, 3/21 sub-
jects) in the TID group. This numeric difference between
two strata was also considered as incidental. Thus, the
relatively small number of subjects in the current trial
precludes drawing conclusions with regard to this obser-
vation. Further investigations are required to accumulate
and evaluate more data in the future.
In a previous US multi-center, randomized, open-label,
parallel group trial for the progesterone vaginal tablet
(ENDOMETRIN: trade name of FE 999913 in the US),
ENDOMETRIN was compared to a progesterone gel
(CRINONE 8 % gel) in women undergoing IVF-ET or
ICSI [17]. This trial included 1211 patients and concluded
that both ENDOMETRIN 100 mg BID and TID were non-
inferior to progesterone gel with respect to ongoing preg-
nancy rate. The ongoing pregnancy rates in this trial ranged
from 38.6 to 42.3 % in the three treatment groups, which is
in line with the US registry data [18]. The different
ongoing pregnancy rates between the current Japanese trial
and the US trial may partly be due to differences in base-
line characteristics. The mean number of embryos trans-
ferred was 1.1 in the Japanese trial and 2.4 in the US trial.
Only 8 % of the embryo transfers were performed on day 5
in the Japanese trial as compared to 30 % or more in the
US trial.
Safety of FE 999913
Adverse events occurred in 38 of 108 subjects (35.2 %).
The most common adverse event was OHSS, which
occurred in 22/108 subjects (20.4 %). However, OHSS is
an adverse event associated with COS and is not related to
FE 999913. The majority of adverse events were mild and
transient and no clinically important events were noted.
In this trial, no new safety issues of concern were
observed that would affect the known safety profile of
FE 999913. No major safety-related problems were iden-
tified, and FE 999913 was well tolerated.
Usefulness of vaginal administration
Preparations of vaginal progesterone include gel, supposi-
tories, and micronized progesterone vaginal inserts. How-
ever, as described previously, no progesterone
preparations, including vaginal preparations, are approved
for the indication of luteal support in ART in Japan.
Therefore, injectable progesterone solutions, oral synthetic
progesterone preparations, or progesterone vaginal prepa-
rations, unofficially imported or dispensed by in-house
pharmacies, are currently used. Treatment with proges-
terone injections is time-consuming and requires daily
visits to the hospital. Additionally, daily injections are
associated with a risk of injection site pain, nerve injury,
and muscle contracture. In the case of imported proges-
terone vaginal preparations, there are concerns regarding
compensation and relief if adverse drug reactions should
occur.
Vaginally administered FE 999913 overcomes the dis-
advantages of progesterone IM injections and will likely
improve patient adherence. Additionally, the concerns
regarding the use of imported vaginal preparations are
addressed. Furthermore, while the vaginal administration
of FE 999913 does not yield high serum concentrations of
progesterone as seen with IM progesterone injections,
higher concentrations can be achieved in the endometrium
than with IM administration [19–21]. The mechanism
responsible is considered to be the direct delivery of pro-
gesterone from the vagina to the uterus (uterine first-pass
effect) [22, 23]. As a result, a reduction in systemic adverse
drug reactions associated with high serum concentrations
was achieved [24–26].
Gel preparations accumulate a significant vaginal build-
up that can be uncomfortable for patients and may induce
vaginal irritation [26]. Meanwhile, the dedicated applicator
enables the delivery of FE 999913 into the depth of the
vaginal cavity. This shortens the distance to the target
organ (endometrium) and resolves the issues seen with the
gel preparations such as discomfort with gel accumulation,
vaginal irritancy, and the necessity for frequent hand
washing.
FE 999913 has been useful overseas as a luteal support
therapy in ART. Results of a nationwide survey of infertile
patients in US undergoing ART, such as IVF, revealed that
patients prefer ENDOMETRIN vaginal inserts to pro-
gesterone-in-oil injections, and to all other vaginal pro-
gesterone supplements. The reasons cited most frequently
for their preference included easy, convenient, and pain-
free administration [27].
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Use of FE 999913 for frozen embryo transfer
In current clinical practice in Japan, frozen embryo transfer
using hormone replacement is frequently performed. The
2012 Ethics Committee Registration/Surveillance Sub-
committee Report (Clinical data for IVF/ET etc. in 2012
and registered institutions as of July 2014) reported that the
efficacy of frozen embryo transfer is higher than that for
fresh embryo transfer [16], with pregnancy rates of 33.7 %
following frozen embryo transfer as compared to 20.8 %
following fresh embryo transfer. In addition, according to
the Japanese nationwide registry data from 2008 to 2010
[28], pregnancy rates after single embryo transfer are
19.0 % in fresh cleaved embryo transfer, 30.0 % in fresh
blastocyst transfer, 19.4 % in thawed cleaved embryo
transfer, and 38.5 % in thawed blastocyst transfer.
FE 999913 is expected to be used in frozen embryo
transfer cycle using hormone replacement, but further
investigations are needed to confirm the efficacy and safety
of FE 999913 in frozen embryo transfer cycles.
Conclusions
The administration of FE 999913 BID or TID up to
10 weeks in Japanese women undergoing fertility treat-
ment with IVF-ET or ICSI could sufficiently supplement
and maintain progesterone concentrations throughout the
treatment period. Additionally, it was confirmed that the
pregnancy rate was similar to that of already approved
Japanese ART drug preparations, and similar to the preg-
nancy rate in actual clinical settings in Japan. The safety
results from the current trial were consistent with the
known safety profile of FE 999913 identified in previous
overseas clinical trials. Thus, treatment with FE 999913
was safe and well tolerated in Japanese women undergoing
IVF-ET or ICSI.
Finally, there is a significant need for the use of a
vaginal progesterone preparation with documented efficacy
and safety in Japanese clinical practice. The use of
FE 999913 in Japan is therefore expected to contribute
greatly to fertility treatment in Japan and to allow luteal
support with a safe, efficacious, and convenient therapy.
Indeed, once FE 999913 is launched with an indication of
‘‘luteal support in ART’’ in Japan, it is expected that
FE 999913 will become the most useful agent for luteal
support in ART.
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